Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients

Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients

BackgroundDue to the waning humoral response after a two-dose SARS-CoV-2 mRNA vaccination, a third booster was recommended in hemodialyis patients. Data on a heterologous mRNA-vector regimen, which might improve immunogenicity, are very limited.MethodsIn this observational study 36 chronic hemodialy...

Full description

Bibliographic Details
Main Authors: Tamara Davidovic, Judith Schimpf, Armin Abbassi-Nik, Richard Stockinger, Hannelore Sprenger-Mähr, Karl Lhotta, Emanuel Zitt
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-06-01
Series:Frontiers in Immunology
Subjects:
Ad26COVS1
COVID-19
hemodialysis
BNT162b2
SARS-CoV-2
vaccination
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.907615/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.907615/full

Similar Items